modelLevetiracetam_1
Extends from Pharmacolibrary.Drugs.ATC.N.N03AX14_1.
Information
| name: | Levetiracetam_1 | |
| ATC code: | N03AX14_1 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 1500 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 0.96 | mL/min/kg |
| other parameters in model implementation | ||
Levetiracetam is an anticonvulsant medication used primarily for the treatment of epilepsy. It is indicated as adjunctive therapy for partial onset seizures, myoclonic seizures, and tonic-clonic seizures in adults and children. Levetiracetam is widely approved and used in clinical practice today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects after intravenous administration.
References
Ong, CLJ, et al., & Kwa, LHA (2021). Pharmacokinetics of levetiracetam in neurosurgical ICU patients. Journal of critical care 64 255–261. DOI:10.1016/j.jcrc.2021.04.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34051579
Klein, P, & Bourikas, D (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. Advances in therapy 41(7) 2682–2699. DOI:10.1007/s12325-024-02876-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/38811492
Toublanc, N, et al., & Andreas, JO (2015). Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration. European journal of drug metabolism and pharmacokinetics 40(4) 461–469. DOI:10.1007/s13318-014-0227-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25283522
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)